Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.

Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD.

Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14074-9. Epub 2007 Aug 20.

2.

Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure.

Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser SR, Molkentin JD.

J Clin Invest. 2007 Sep;117(9):2431-44.

3.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
4.

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition.

Meloche S, Pouysségur J.

Oncogene. 2007 May 14;26(22):3227-39. Review.

PMID:
17496918
5.

Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

Owens DM, Keyse SM.

Oncogene. 2007 May 14;26(22):3203-13. Review.

PMID:
17496916
6.

ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes.

Frémin C, Ezan F, Boisselier P, Bessard A, Pagès G, Pouysségur J, Baffet G.

Hepatology. 2007 Apr;45(4):1035-45.

PMID:
17393467
7.

Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.

Li C, Scott DA, Hatch E, Tian X, Mansour SL.

Development. 2007 Jan;134(1):167-76.

8.

The MEK/ERK cascade: from signaling specificity to diverse functions.

Shaul YD, Seger R.

Biochim Biophys Acta. 2007 Aug;1773(8):1213-26. Epub 2006 Oct 19. Review.

9.

Mapping ERK2-MKP3 binding interfaces by hydrogen/deuterium exchange mass spectrometry.

Zhou B, Zhang J, Liu S, Reddy S, Wang F, Zhang ZY.

J Biol Chem. 2006 Dec 15;281(50):38834-44. Epub 2006 Oct 17.

10.

Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy.

Parsons SA, Millay DP, Sargent MA, McNally EM, Molkentin JD.

Am J Pathol. 2006 Jun;168(6):1975-85.

11.

Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3.

Liu S, Sun JP, Zhou B, Zhang ZY.

Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5326-31. Epub 2006 Mar 27.

12.

Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability.

Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD.

Circ Res. 2006 Mar 31;98(6):837-45. Epub 2006 Mar 2.

13.

B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK.

Letourneux C, Rocher G, Porteu F.

EMBO J. 2006 Feb 22;25(4):727-38. Epub 2006 Feb 2.

14.

Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes.

Adams DG, Coffee RL Jr, Zhang H, Pelech S, Strack S, Wadzinski BE.

J Biol Chem. 2005 Dec 30;280(52):42644-54. Epub 2005 Oct 20.

15.

The role of erk1 and erk2 in multiple stages of T cell development.

Fischer AM, Katayama CD, Pagès G, Pouysségur J, Hedrick SM.

Immunity. 2005 Oct;23(4):431-43.

16.

Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo.

Kaiser RA, Liang Q, Bueno O, Huang Y, Lackey T, Klevitsky R, Hewett TE, Molkentin JD.

J Biol Chem. 2005 Sep 23;280(38):32602-8. Epub 2005 Jul 25.

17.

Protein phosphatase 2A regulates apoptosis in neutrophils by dephosphorylating both p38 MAPK and its substrate caspase 3.

Alvarado-Kristensson M, Andersson T.

J Biol Chem. 2005 Feb 18;280(7):6238-44. Epub 2004 Nov 29.

18.

Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes.

Liu Q, Hofmann PA.

Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2204-12. Epub 2004 Feb 12.

PMID:
14962831
19.

Bcl-2 overexpression corrects mitochondrial defects and ameliorates inherited desmin null cardiomyopathy.

Weisleder N, Taffet GE, Capetanaki Y.

Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):769-74. Epub 2004 Jan 8.

20.

Supplemental Content

Support Center